The choice of this approach is partially based on the documented synergy of c-Met and EGFR in driving oncogenesis in both EGFR wild type (WT) and mutant lung cancer models, in the setting of acquired resistance to EGFR-TKIs. This evidence concerns the gene EGFR and lung carcinoma.